北京键凯科技股份有限公司监事会 2024 年 8 月 28 日 北京键凯科技股份有限公司（以下简称"公司"）监事会根据《中华人民共和国公 司法》、《中华人民共和国证券法》、《上市公司股权激励管理办法》、《上海证券交 易所科创板股票上市规则》等相关法律、法规、规范性文件及《北京键凯科技股份有限 公司章程》（以下简称"《公司章程》"）的有关规定，对公司 2021 年限制性股票激 励计划预留授予部分第二个归属期归属名单进行审核，发表核查意见如下： 本次拟归属的预留授予部分第二个归属期 17 名激励对象对应考核年度的个人绩效 考核结果全部达标。拟归属的激励对象符合《中华人民共和国公司法》《中华人民共和 国证券法》等法律、法规和规范性文件以及《公司章程》规定的任职资格，符合《上市 公司股权激励管理办法》《上海证券交易所科创板股票上市规则》等法律、法规和规范 性文件规定的激励对象条件，符合《2021 年限制性股票激励计划》规定的激励对象范围， 其作为公司本次限制性股票激励计划激励对象的主体资格合法、有效，激励对象获授限 制性股票的归属条件已成就。 北京键凯科技股份有限公司监事会 关于公司 2021 年限制性股票激励计划预 ...

证券代码：688356 证券简称：键凯科技 公告编号：2024-032 北京键凯科技股份有限公司 2024 年半年度募集资金存放与使用情况的专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、募集资金基本情况 （一）实际募集资金金额及到账时间 根据中国证券监督管理委员会于 2020 年 7 月 28 日签发的证监许可[2020] 1579 号文《关于同意北京键凯科技股份有限公司首次公开发行股票注册的批 复》，北京键凯科技股份有限公司(以下简称"北京键凯"或"公司")于 2020 年 8 月向社会公众发行人民币普通股 15,000,000 股，每股发行价格为人民币 41.18 元，股款以人民币缴足，计人民币 617,700,000.00 元，扣除承销费用含 增值税金额人民币 52,380,960.00 元(不含增值税金额为人民币 49,416,000.00 元)，扣除此承销费用含增值税金额后，实际收到募集资金人民币 565,319,040.00 元(以下简称"募集资金")。除上述承销费用外，本公司发生 了其他发行费 ...

Financial Performance - The company reported a revenue of RMB 500 million for the first half of 2024, representing a 20% increase compared to the same period last year[10]. - The company's operating revenue for the first half of 2024 was ¥128,587,088.02, a decrease of 24.99% compared to ¥171,429,143.90 in the same period last year[15]. - Net profit attributable to shareholders was ¥27,944,793.02, down 59.06% from ¥68,260,481.92 year-on-year[15]. - The net cash flow from operating activities decreased by 38.35% to ¥68,587,891.20 from ¥111,261,003.75 in the previous year[15]. - Basic earnings per share fell to ¥0.46, a decline of 59.17% compared to ¥1.13 in the same period last year[16]. - The overall gross profit margin was 67.13%, down 11.09 percentage points year-on-year, with product sales gross margin at 66.76%, a decrease of 9.08 percentage points[36]. - The company achieved a net profit available for distribution to shareholders of 10% for the current year, with cumulative cash distributions over the past three years amounting to no less than 30% of the average annual distributable profit during the same period[77]. Research and Development - The R&D expenditure for the first half of 2024 was RMB 80 million, accounting for 16% of total revenue, reflecting the company's commitment to innovation[10]. - The company's R&D expenditure accounted for 21.73% of operating revenue, an increase of 5.29 percentage points from the previous year[17]. - The company has developed several PEG-modified drugs and Class III medical devices, with ongoing clinical trials for PEG-irinotecan and other products[21]. - The company has completed the development of 46 new structural derivatives and 79 analytical methods during the reporting period[34]. - The company is actively developing new PEG-modified drugs and medical devices, with ongoing projects in tumor treatment and medical aesthetics[28]. - The company employs 85 R&D personnel, accounting for 29.21% of the total workforce, with an average salary of ¥15.91[33]. Market Expansion and Strategy - The company aims for a revenue growth target of 25% for the full year 2024, driven by market expansion and new product launches[10]. - The company has identified key markets for expansion, including Southeast Asia and Europe, with plans to establish local partnerships[10]. - The company is exploring potential acquisitions to enhance its product portfolio and market presence, with a focus on companies in the biotechnology sector[10]. - The company plans to launch two new products in Q3 2024, which are expected to contribute an additional RMB 100 million in revenue[10]. Financial Integrity and Governance - The company has no significant non-operating fund occupation by controlling shareholders or related parties, ensuring financial integrity[10]. - The company has committed to fulfilling all public promises made during the issuance process and will accept social supervision[77]. - There were no significant lawsuits or arbitration matters during the reporting period[80]. - The company has not engaged in any non-operating fund occupation by controlling shareholders or related parties during the reporting period[80]. Environmental Responsibility - The company has invested in necessary environmental protection facilities, ensuring that all facilities operate effectively and meet discharge requirements[62]. - The company has established mechanisms for environmental protection and is committed to sustainable practices[57]. - The company has implemented various pollution control measures, including wastewater treatment facilities using hydrolysis + UASB + A/O biochemical treatment processes[62]. - The company has established an emergency response command and regularly conducts drills to manage potential environmental risks[64]. Inventory and Receivables Management - The total accounts receivable at the end of the period was ¥77,765,025.95, down from ¥119,119,744.91, indicating a decrease of about 34.73%[176]. - The aging analysis of accounts receivable showed that receivables overdue by more than 90 days amounted to ¥16,849,314.15, with a provision for bad debts of ¥540,208.45, representing a provision rate of 3.21%[179]. - The inventory balance as of June 30, 2024, is RMB 122,615,441.87, which includes a provision for inventory depreciation of RMB 28,399,701.30[196]. - The total amount of other current assets at the end of the period is RMB 8,521,345.25, an increase from RMB 6,885,242.08 at the beginning of the year, representing a growth of approximately 23.7%[199]. Shareholder and Capital Management - The company plans to enhance the competitiveness of existing business segments to improve profitability and reduce costs, aiming for increased revenue and profit margins[74]. - The company will implement a three-year dividend return plan to optimize the investment return mechanism for shareholders[75]. - The company has committed to a profit distribution policy that prioritizes cash dividends, with a minimum cash dividend ratio of 80% during mature stages without major capital expenditures[76]. - The company will ensure that profit distribution does not exceed the cumulative distributable profits and does not impair its ongoing operational capabilities[76].

证券代码：688356 证券简称：键凯科技 公告编号：2024-029 北京键凯科技股份有限公司 第三届监事会第七次会议决议公告 本次会议以书面表决方式进行表决。经与会监事认真审议，一致通过以下议案： （一）审议通过《关于公司 2024 年半年度报告及其摘要的议案》 经审核，监事会认为公司 2024 年半年度报告的编制和审议程序符合相关法律法规 及公司章程等内部规章制度的规定；公司 2024 年半年度报告的内容与格式符合相关规 定，公允地反映了公司 2024 年半年度的财务状况和经营成果等事项；半年度报告编制 过程中，未发现公司参与半年度报告编制和审议的人员有违反保密规定的行为；监事会 全体成员保证公司 2024 年半年度报告披露的信息真实、准确、完整，不存在任何虚假 记载、误导性陈述或重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责 任。 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、 监事会会议召开情况 北京键凯科技股份有限公司（以下简称"公司"）第三届监事会第七次会议通知已 于 2024 年 8 月 ...

证券代码：688356 证券简称：键凯科技 公告编号：2024-027 北京键凯科技股份有限公司 关于以集中竞价交易方式回购股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2024/2/22，由公司实际控制人、董事长 XUANZHAO （赵宣）先生提议 | | --- | --- | | 回购方案实施期限 | 2024/2/21~2025/2/20 | | 预计回购金额 | 万元 1,000 万元~2,000 | | 回购用途 | 用于员工持股计划或股权激励 | | 累计已回购股数 | 万股 14.7914 | | 累计已回购股数占总股本比例 | 0.2440% | | 累计已回购金额 | 1,050.03 万元 | | 实际回购价格区间 | 62.85 元/股~75.05 元/股 | 一、 回购股份的基本情况 2024 年 2 月 21 日，北京键凯科技股份有限公司（以下简称"公司"）召开第 三届董事会第七次会议，审议通过了《关于以集中竞价交易方式回购公司股份方 案 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 证券代码：688356 证券简称：键凯科技 公告编号：2024-026 北京键凯科技股份有限公司 关于以集中竞价交易方式回购股份的进展公告 一、 回购股份的基本情况 2024 年 2 月 21 日，北京键凯科技股份有限公司（以下简称"公司"）召开第 三届董事会第七次会议，审议通过了《关于以集中竞价交易方式回购公司股份方 案的议案》，同意公司使用不低于人民币 1000 万元（含），不超过人民币 2000 万 元（含）的自有资金以集中竞价交易方式回购公司股份，用于实施股权激励或员 工持股计划，并将在公司披露股份回购实施结果暨股份变动公告后 3 年内使用完 毕；若未能在规定期限内使用完毕，董事会将依法履行减少注册资本的程序，尚 未使用的已回购股份将被注销。回购期限为自董事会审议通过本次回购股份方案 之日起 12 个月内，回购价格最高不超过人民币 125.22 元/股。具体内容详见公司 于 2024 年 2 月 22 日披露于上海证券交易所网站（www.sse.com.c ...

证券代码：688356 证券简称：键凯科技 公告编号：2024-025 北京键凯科技股份有限公司 关于 2023 年年度报告的信息披露监管问询函的 回复公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 北京键凯科技股份有限公司于近日收到上海证券交易所下发的《关于北京键 凯科技股份有限公司 2023 年年度报告的信息披露监管问询函》（上证科创公函 【2024】0181 号），公司就函件关注的相关问题逐项进行了认真的核查落实，现 就函件相关问题回复如下： 本回复中若出现合计数与各项目直接相加之和存在尾数差异，均为四舍五入 所致。如无特别说明，本回复中使用的简称、名词释义与《北京键凯科技股份有 限公司 2023 年年度报告》一致。 问题 1：关于经营业绩 年报显示，受下游行业整体趋势影响，叠加 LNP 相关业务收入的减少、部 分主要客户订单交付节奏变动以及技术服务协议到期等因素，公司 2023 年收入 与利润端承压明显，实现营业收入 2.92 亿元，同比下降 28.26%，归母净利润 1.16 亿元，同比下降 38.05%。 ...

中信证券股份有限公司关于 北京键凯科技股份有限公司 2023 年年度报告的信息披露监管问询函 回复的核查意见 保荐人（主承销商） 深圳市福田区中心三路 8 号卓越时代广场（二期）北座 1 上海证券交易所： 根据贵所于 2024 年 6 月 11 日出具的《关于北京键凯科技股份有限公司 2023 年年度报告的信息披露监管问询函》（上证科创公函【2024】0181 号，以下简称 "问询函"）的有关要求，中信证券股份有限公司（以下简称"中信证券"）作为 北京键凯科技股份有限公司（以下简称"公司"或"键凯科技"）首次公开发行 股票并在科创板上市的保荐机构及持续督导机构，现将有关问题出具专项意见如 下： 2 问题 1：关于经营业绩 年报显示，受下游行业整体趋势影响，叠加 LNP 相关业务收入的减少、部 分主要客户订单交付节奏变动以及技术服务协议到期等因素，公司 2023 年收入 与利润端承压明显，实现营业收入 2.92 亿元，同比下降 28.26%，归母净利润 1.16 亿元，同比下降 38.05%。2024 年一季度，公司实现营业收入 0.65 亿元，同比下 降 30.20%，归母净利润 0.14 亿元，同比下降 6 ...

问题二.关于国外业务。年报显示，公司采用直销模式开展境内外销售。2023 年，国外地 区营业收入为 1.42 亿元，同比下降 25.56%，占主营业务收入的比重为 48.56%，国外地区 毛利率为 89.10%，高于国内地区毛利率 15.27 个百分点。 请你公司：(1)结合2023年国外前五大客户的主要情况，包括但不限于成立时间、销售内容 、销售金额及合作历史等，说明上市以来国外主要客户的变动情况及变动原因。(2)结合 2023年国外销售收入的区域分布、下游行业分布，说明上市以来国外销售的区域、行业分布 有无重要变化，如有，请说明原因。（3）结合产品结构、收入构成、同行业可比业务毛利率 等，分析并说明公司国内外销售毛利率差异原因及合理性。请年审会计师说明：（1）对境外 收入的审计程序及其充分性、有效性，包括但不限于境外客户的函证与走访情况，与出口退 税、外管局收汇数据、中信保数据等第三方数据的验证及匹配情况等；（2）公司境外客户应 收账款期后收回情况，未收回账款对应的客户及原因，销售商品、提供劳务收到的现金与收 入是否匹配。 （一） 结合2023年国外前五大客户的主要情况，包括但不限于成立时间、销售内容、销 ...

Summary of the Conference Call for JianKai Technology Company Overview - **Company Name**: JianKai Technology - **Industry**: Pharmaceutical and Medical Devices Key Points and Arguments Company Performance and Developments - The company has faced challenges in its recent annual and quarterly reports, indicating that the data was not ideal, but there is potential for future growth due to the clearing of special market conditions and the return of excessive technical service fees to initial levels [3][4] - JianKai's first international new drug project has been approved for listing in the U.S., marking a significant milestone in the company's international innovation efforts [3][4] - Two PEGylated drugs supported by JianKai received market approval in China in 2023, with several other late-stage clinical projects also in the pipeline [6][8] Research and Development - The company maintained a high level of R&D investment, totaling over 57 million, which accounts for 17.079% of sales revenue, indicating a commitment to innovation despite market challenges [8] - JianKai is actively pursuing clinical trials for various products, including a compound sodium hyaluronate solution, with expectations to complete clinical trials by Q4 2024 [10] Market Strategy and Future Outlook - The company is focusing on expanding its application of innovative materials and medical devices, with new applications emerging in 2023 [7][8] - JianKai is optimistic about the future of its medical aesthetics segment, with ongoing clinical trials and product approvals expected to drive growth [17][19] - The company is also exploring new customer relationships and maintaining communication with existing clients to adapt to market demands [29][38] Competitive Landscape - The competitive landscape in the PET market is evolving, with domestic pricing having a more significant impact than international pricing [34][35] - The company is adjusting its pricing strategies based on market dynamics and customer negotiations, ensuring that gross margins are maintained [35] Clinical Trials and Product Development - The company is in the process of advancing its clinical trials for various products, including small cell lung cancer treatments, with ongoing preparations for patient enrollment [25][27] - There is a focus on ensuring compliance and thoroughness in clinical trial processes, which can be time-consuming but is essential for product integrity [16][28] Investor Communication - The company emphasizes the importance of transparency and communication with investors, assuring them that updates will be provided as significant developments occur [26][39] - There is a recognition of the need for patience from investors regarding the timelines for product approvals and clinical trial results [20][21] Additional Important Information - The company is actively working on multiple fronts, including the development of innovative medical devices and pharmaceuticals, while also managing existing product lines and customer relationships [41][42] - The management is committed to maintaining a balance between innovation and operational efficiency, ensuring that the company remains competitive in a challenging market environment [11][12][41]